Laura M Fernandez
Overview
Explore the profile of Laura M Fernandez including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
33
Citations
342
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Fernandez L, Sao Juliao G, Cerdan-Santacruz C, Renehan A, Beets G, Parvaiz A, et al.
J Clin Oncol
. 2025 Mar;
:JCO2500132.
PMID: 40080773
No abstract available.
2.
Sao Juliao G, Fernandez L, Vailati B, Corbi L, Denost Q, Perez R
Dis Colon Rectum
. 2025 Jan;
68(2):e54.
PMID: 39847804
No abstract available.
3.
Fernandez L, Sao Juliao G, Cerdan Santacruz C, Renehan A, Cano-Valderrama O, Beets G, et al.
J Clin Oncol
. 2024 Oct;
:JCO2400405.
PMID: 39467217
Purpose: Organ preservation has become an attractive alternative to surgery (total mesorectal excision [TME]) among patients with rectal cancer after neoadjuvant therapy who achieve a clinical complete response (cCR). Nearly...
4.
Herrando A, Fernandez L, Azevedo J, Vieira P, Domingos H, Galzerano A, et al.
Sci Rep
. 2024 Oct;
14(1):24575.
PMID: 39426971
Colorectal cancer (CRC) ranks among the most prevalent malignancies worldwide, driving a quest for comprehensive characterization methods. We report a characterization of the ex vivo autofluorescence lifetime fingerprint of colorectal...
5.
Zebrafish Avatar-test forecasts clinical response to chemotherapy in patients with colorectal cancer
Costa B, Estrada M, Gomes A, Fernandez L, Azevedo J, Povoa V, et al.
Nat Commun
. 2024 Jun;
15(1):4771.
PMID: 38839755
Cancer patients often undergo rounds of trial-and-error to find the most effective treatment because there is no test in the clinical practice for predicting therapy response. Here, we conduct a...
6.
El Sissy C, Kirilovsky A, Lagorce Pages C, Marliot F, Custers P, Dizdarevic E, et al.
J Clin Oncol
. 2023 Oct;
42(1):70-80.
PMID: 37788410
Purpose: No biomarker capable of improving selection and monitoring of patients with rectal cancer managed by watch-and-wait (W&W) strategy is currently available. Prognostic performance of the Immunoscore biopsy (IS) was...
7.
Fernandez L, Sao Juliao G, Renehan A, Beets G, Papoila A, Vailati B, et al.
Dis Colon Rectum
. 2023 Jul;
66(10):e1054-e1055.
PMID: 37493212
No abstract available.
8.
Sao Juliao G, Fernandez L, Vailati B, Habr-Gama A, Azevedo J, Santiago I, et al.
Dis Colon Rectum
. 2023 Jul;
67(1):73-81.
PMID: 37493198
Background: A proportion of rectal cancer patients who achieve a clinical complete response may develop local regrowth. Although salvage appears to provide appropriate local control, the risk of distant metastases...
9.
Fernandez L, Sao Juliao G, Renehan A, Beets G, Papoila A, Vailati B, et al.
Dis Colon Rectum
. 2022 Dec;
66(1):41-49.
PMID: 36515514
Background: Nearly 30% of patients with rectal cancer develop local regrowth after initial clinical complete response managed by watch and wait. These patients might be at higher risk for distant...
10.
Herrando A, Azevedo J, Fernandez L, Vieira P, Heald R, Parvaiz A
Colorectal Dis
. 2022 Nov;
25(5):1043.
PMID: 36357157
No abstract available.